Mark Berger

Technik-/Wissenschafts-/F&E-Leiter bei GENPREX, INC.

Vermögen: 3 862 $ am 30.06.2026

71 Jahre

Health Technology

Consumer Services

Profil

Mark S.
Berger is currently Chief Medical Officer at Genprex, Inc. since 2021.
Former positions include Senior Director-Oncology Clinical Development at Wyeth Pharmaceuticals LLC; Group Director-Clinical Oncology at GSK Plc from 2002 to 2007; Principal at the University of Pennsylvania; Vice President-Clinical Development at Gemin X Pharmaceuticals US, Inc. from 2007 to 2011; Chief Medical Officer at Deciphera Pharmaceuticals LLC from 2011 to 2013; Senior Vice President-Clinical Research at Kadmon Corp.
LLC from 2013 to 2017; and Chief Medical Officer at Actinium Pharmaceuticals, Inc. from 2017 to 2021.
Education includes undergraduate studies at Wesleyan University and a doctorate from The University of Virginia School of Medicine.

Bekannte Unternehmensbeteiligungen

Unternehmen	Datum	Anzahl der Aktien	Bewertung	Datum der Bewertung
GENPREX INC 0,07 %	15.04.2026	7.442 ( 0,07 % )	3 862 $	30.06.2026

Aktive Positionen von Mark Berger

Unternehmen	Position	Beginn
GENPREX, INC.	Technik-/Wissenschafts-/F&E-Leiter	27.09.2021

Alle aktiven Positionen von Mark Berger

Ehemalige bekannte Positionen von Mark Berger

Unternehmen	Position	Ende
ACTINIUM PHARMACEUTICALS, INC.	Technik-/Wissenschafts-/F&E-Leiter	24.09.2021
Kadmon Corp. LLC Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products	Technik-/Wissenschafts-/F&E-Leiter	01.01.2017
Deciphera Pharmaceuticals LLC Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Discovers and develops pharmaceutical preparations	Technik-/Wissenschafts-/F&E-Leiter	01.09.2013
Gemin X Pharmaceuticals US, Inc. Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Develops cancer therapeutic products	Corporate Officer/Principal	01.06.2011
GSK PLC	Corporate Officer/Principal	01.02.2007

Sehen Sie sich die Erfahrung von Mark Berger im Detail an

Ausbildung von Mark Berger

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen

Sehen Sie sich die Erfahrung von Mark Berger im Detail an

Beziehungen

Beziehungen ersten Grades

Unternehmen ersten Grades

Herr

Frau

Aufsichtsräte

Führungskräfte

Sehen Sie sich das persönliche Netzwerk an

Unternehmensverbindungen

Private Unternehmen	10
Wyeth Pharmaceuticals LLC Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets infant pharmaceutical products	Health Technology
Genprex, Inc. Genprex, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular therapies for cancer treatment	Health Technology
GSK Plc GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products	Health Technology
University of Pennsylvania University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Wesleyan University Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
Gemin X Pharmaceuticals US, Inc. Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Develops cancer therapeutic products	Health Technology
Deciphera Pharmaceuticals LLC Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Discovers and develops pharmaceutical preparations	Health Technology
Kadmon Corp. LLC Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products	Health Technology
Actinium Pharmaceuticals, Inc. Actinium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers	Health Technology
The University of Virginia School of Medicine The University of Virginia School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services